Igeneon Licenses Cancer Vaccine from Novartis

By Business Review Editor

Pharma Deals Review: Vol 2002 Issue 29 (Table of Contents)

Published: 2 Oct-2002

DOI: 10.3833/pdr.v2002.i29.992     ISSN: 1756-7874

Section: Licensing



Igeneon entered into a licensing agreement with Novartis for an anti-idiotypic antibody cancer vaccine, IGN301 that targets epithelial antigens for the treatment of epithelial cancers...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details